Open Access



Erratum to: A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

Hiroshi Kato^{1,2*}, Masayuki Miyazaki^{1,2}, Mio Takeuchi², Hiroaki Tsukuura³, Mihoko Sugishita³, Yukihiro Noda^{1,2} and Kiyofumi Yamada¹

Erratum

Unfortunately, after publication of the original version of this article [1], it was noticed that some author corrections were not included in the final article.

• Within the "Methods" section, the Cockcroft-Gault equation should read as follows:

• In addition Table 1 contained some formatting errors. The correct version of Table 1 is included below.

* Correspondence: hk-hiroshi@med.nagoya-u.ac.jp

¹Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan

Full list of author information is available at the end of the article



© 2016 Kato et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

²Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan

Table 1 Patient characteristics (n = 204)

| Age | |
|--|-------------|
| Median, year | 61 |
| Range, year | 18-92 |
| Gender | |
| Male, <i>n</i> (%) | 123 (60.3) |
| Female , <i>n</i> (%) | 81 (39.7) |
| Median CLcr ^a , mL/min | 88.7 |
| NP ^b origin | |
| Cancer related NP, <i>n</i> (%) | 55 (27.0) |
| Chemotherapy related NP, n(%) | 24 (11.7) |
| Non-cancer related NP, <i>n</i> (%) | 125 (61.3) |
| Regular strong opioid | |
| yes, n(%) | 36 (17.6) |
| -fentanyl, <i>n</i> | 17 |
| -oxycodone, <i>n</i> | 16 |
| -morphine, n | 3 |
| Median dose ^c (range), mg/day | 60 (15–300) |
| no, <i>n</i> (%) | 168 (82.4) |
| Initial dose of pregabalin | |
| 150 mg/day, <i>n</i> (%) | 124 (60.8) |
| 75 mg/day, <i>n</i> (%) | 73 (35.8) |
| 50 mg/day, <i>n</i> (%) | 3 (1.5) |
| 25 mg/day, <i>n</i> (%) | 4 (1.9) |

^aCLcr: creatinine clearance using the Cockcroft-Gault equation ^bNP: neuropathic pain ^cconverted to oral morphine

Author details

¹Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan. ²Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan. ³Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

Received: 11 February 2016 Accepted: 11 February 2016 Published online: 17 February 2016

References

 Kato H, Miyazaki M, Takeuchi M, Tsukuura H, Sugishita M, Noda Y, et al. A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin. J Pharm Health Care Sci. 2015;1:22. doi:10.1186/s40780-015-0022-7.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

